Prostate Health Global Market Report 2025

The prostate health market size has grown strongly in recent years. It will grow from $34.07 billion in 2024 to $37.34 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth during the historic period can be attributed to an aging population, increased PSA screening, rising awareness campaigns, advancements in hormone therapy, and growing incidence rates.

The prostate health market size is expected to see strong growth in the next few years. It will grow to $53.25 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the growing adoption of precision medicine, increasing use of AI-driven diagnostics, the expansion of targeted radiotherapies, rising demand for minimally invasive treatments, and improved genetic profiling for risk assessment. Key trends expected during this period include AI-powered risk assessment, advancements in liquid biopsy, next-generation radiotheranostics, innovations in immunotherapy, and real-time biomarker monitoring.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate health market. Prostate cancer occurs when cells in the prostate gland grow uncontrollably, with adenocarcinomas being the most common form in men. The rise in prostate cancer cases is primarily attributed to an aging population, increased screening practices, and lifestyle factors such as obesity and physical inactivity. Maintaining prostate health is crucial for preventing, detecting, and managing prostate cancer. For example, in January 2023, the American Cancer Society (ACS), a US-based nonprofit organization, projected approximately 288,300 new prostate cancer diagnoses in the U.S. in 2023, with an estimated 34,700 fatalities. As a result, the growing prevalence of prostate cancer is fueling the expansion of the prostate health market.

Leading companies in the prostate health market are leveraging technological advancements such as AI-powered risk assessment to enhance diagnostic accuracy and reduce unnecessary biopsies. AI-powered risk assessment utilizes artificial intelligence algorithms to analyze data, predict potential risks, and support informed decision-making for improved patient outcomes. For instance, in September 2024, Nanostics Inc., a Canada-based clinical-stage biotechnology company, partnered with Protean BioDiagnostics, a US-based biotechnology company, to launch CDX Prostate, a diagnostic tool designed for men at risk of aggressive prostate cancer. This tool integrates biological data, clinical information, and AI-powered learning models to generate a risk score, offering a more precise assessment compared to traditional methods. CDX Prostate assists healthcare providers and patients in determining whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or an abnormal digital rectal exam (DRE).

In June 2024, Lantheus Holdings Inc., a US-based radiopharmaceutical company, acquired worldwide rights to Life Molecular Imaging's RM2 for an undisclosed amount. This acquisition aims to strengthen Lantheus' presence in prostate cancer treatment while expanding its pipeline to include breast and other cancers. RM2 is a novel radiotheranostic pair, including 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target the gastrin-releasing peptide receptor (GRPR). Life Molecular Imaging, a Germany-based radiopharmaceutical company, specializes in developing innovative radiopharmaceuticals to enhance early detection and diagnosis of chronic and life-threatening conditions.

Major players in the prostate health market are Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Bayer AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc, Genentech Inc., Teleflex Inc., Elekta AB, Myriad Genetics Inc., Freenome, Theragenics Corporation, CureVac BV, ArsenalBio, Roivant Sciences, Artera Inc., Veru Inc., HistoSonics Inc., Immunic Inc., Ezra, Francis Medical, CorTechs Labs, Lucida Medical, Serimmune Inc., and Alessa Therapeutics.

North America was the largest region in the prostate health market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prostate health report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prostate health encompasses the overall well-being and proper functioning of the prostate gland, a small organ in men responsible for producing seminal fluid. Maintaining prostate health is crucial for urinary function, reproductive health, and the prevention of conditions such as prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Factors affecting prostate health include age, genetics, diet, lifestyle, and regular medical screenings.

The primary disease indications related to prostate health include prostate cancer, benign prostatic hyperplasia, and prostatitis. Prostate cancer originates in the prostate gland and is characterized by the uncontrolled growth of prostate cells, potentially leading to tumor formation and metastasis. Treatment options include hormonal therapy, chemotherapy, surgical procedures, and other approaches. Various distribution channels for prostate health treatments include e-commerce stores, pharmacies, and other outlets.

The prostate health market research report is one of a series of new reports that provides prostate health market statistics, including prostate health industry global market size, regional shares, competitors with a prostate health market share, detailed prostate health market segments, market trends and opportunities, and any further data you may need to thrive in the prostate health industry. This prostate health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate health market includes revenues earned by entities providing services such as diagnostic screening, medical consultations, prostate cancer treatments, minimally invasive procedures for benign prostatic hyperplasia (BPH), telemedicine consultations, and wellness programs focused on prostate health. Only goods and services traded between entities or sold to end consumers are included. The prostate health market consists of sales of pharmaceuticals, medical devices, dietary supplements, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.